What oral hypoglycemic agents (OHAs) should be continued alongside Tirzepatide (a glucagon-like peptide-1 (GLP-1) receptor agonist) in a patient with hyperglycemia (HbA1c 9%) and obesity, who is being transitioned from Sitagliptin (a dipeptidyl peptidase-4 (DPP-4) inhibitor) and Glimepiride (a sulfonylurea) to Tirzepatide, with planned addition of Dapagliflozin (a sodium-glucose cotransporter 2 (SGLT2) inhibitor) and continuation of Metformin (a biguanide)?

Medication Management for Tirzepatide Transition in Obese Patient with HbA1c 9%

Direct Recommendation

Continue metformin 2 grams daily and add dapagliflozin 10 mg daily to tirzepatide, while discontinuing both sitagliptin and glimepiride immediately. 1, 2

---

Rationale for Each Medication Decision

Metformin: Continue at Current Dose

• Metformin should be continued as the foundational therapy for type 2 diabetes, providing cardiovascular benefits and serving as the backbone for combination therapy 1
• The majority of patients in cardiovascular outcomes trials for both GLP-1 receptor agonists and SGLT2 inhibitors were on background metformin therapy, establishing the evidence base for this combination 1
• Metformin can be safely continued with tirzepatide without dose adjustment, as there is minimal hypoglycemia risk with this combination 2
• Continue the current dose of 2 grams daily unless eGFR falls below 45 mL/min/1.73 m², at which point dose reduction would be necessary 1, 2

Sitagliptin: Discontinue Immediately

• Stop sitagliptin when initiating tirzepatide because both agents work through incretin-based mechanisms, and combining a DPP-4 inhibitor with a GLP-1 receptor agonist provides no additional benefit 1
• Tirzepatide, as a dual GIP/GLP-1 receptor agonist, has substantially greater efficacy than DPP-4 inhibitors for both glycemic control and weight reduction 3
• There is no evidence supporting concomitant use of DPP-4 inhibitors with GLP-1 receptor agonists, and guidelines do not recommend this combination 1

Glimepiride: Discontinue Immediately

• Discontinue glimepiride before starting tirzepatide to minimize hypoglycemia risk, particularly given the patient's HbA1c of 9% which will drop significantly with tirzepatide 1, 4
• Sulfonylureas carry substantial hypoglycemia risk when combined with potent glucose-lowering agents like tirzepatide, especially as glycemic control improves 1, 4
• The dose adjustment strategy of reducing sulfonylureas by 50% is insufficient when initiating a highly effective agent like tirzepatide in a patient with HbA1c 9%—complete discontinuation is safer 4
• Tirzepatide will provide superior glycemic control compared to glimepiride without the weight gain and hypoglycemia risk associated with sulfonylureas 5, 6

Dapagliflozin: Add 10 mg Daily

• Add dapagliflozin 10 mg once daily for complementary cardiovascular and renal protection, as SGLT2 inhibitors and GLP-1 receptor agonists have additive benefits through different mechanisms 1, 2
• Dapagliflozin provides cardiovascular mortality reduction, heart failure hospitalization reduction, and renal protection independent of glucose-lowering effects 1, 2
• The combination of an SGLT2 inhibitor with a GLP-1 receptor agonist is explicitly recommended in current guidelines to provide complementary outcomes benefits 1
• Use the fixed dose of 10 mg daily without titration for cardiovascular and renal protection, assuming eGFR ≥25 mL/min/1.73 m² 2
• For glycemic control purposes, dapagliflozin should only be initiated if eGFR ≥45 mL/min/1.73 m², but cardiovascular/renal benefits persist at lower eGFR levels 2

---

Implementation Algorithm

Step 1: Verify Patient Eligibility for Dapagliflozin

• Check eGFR: must be ≥25 mL/min/1.73 m² for initiation 2
• Assess volume status and correct any volume depletion before starting 2
• Confirm patient is not pregnant or planning major surgery within 3 days 2

Step 2: Medication Changes on Day 1

• Stop: Sitagliptin 100 mg and Glimepiride 1 mg 1, 4
• Continue: Metformin 2 grams daily 1
• Start: Tirzepatide 2.5 mg subcutaneously weekly 3
• Start: Dapagliflozin 10 mg orally once daily 2

Step 3: Tirzepatide Dose Escalation

• Increase tirzepatide to 5 mg weekly after 4 weeks 3
• Further escalation to 7.5 mg, 10 mg, or 15 mg weekly can occur at 4-week intervals based on glycemic response and tolerability 3

Step 4: Monitoring Schedule

• Check eGFR within 1-2 weeks after starting dapagliflozin (expect a small reversible decrease of 3-5 mL/min/1.73 m²) 2
• Monitor blood glucose closely during the first 2-4 weeks to assess response 2
• Recheck HbA1c at 12 weeks to assess glycemic response 1
• Monitor for genital mycotic infections (occurs in ~6% of patients on SGLT2 inhibitors) 2

---

Critical Safety Considerations

Hypoglycemia Prevention

• The combination of metformin, tirzepatide, and dapagliflozin has very low hypoglycemia risk since none of these agents directly stimulate insulin secretion 2, 6
• Discontinuing glimepiride eliminates the primary hypoglycemia risk in this regimen 4, 5

Sick Day Management

• Instruct patient to stop dapagliflozin during acute illness with fever, vomiting, diarrhea, or reduced oral intake 2
• Continue metformin unless eGFR drops acutely or patient develops severe illness 2
• Continue tirzepatide unless patient cannot tolerate oral intake for >24 hours 2

Euglycemic Diabetic Ketoacidosis (DKA)

• Educate patient about DKA symptoms (nausea, vomiting, abdominal pain, malaise) even with normal blood glucose 2
• Withhold dapagliflozin at least 3 days before any major surgery or procedure requiring prolonged fasting 2

Volume Depletion

• Monitor for orthostatic hypotension, dizziness, or dehydration, especially in the first 2 weeks 2
• Consider reducing any concurrent diuretic doses if patient develops volume depletion symptoms 2

---

Expected Outcomes

Glycemic Control

• Tirzepatide will provide substantial HbA1c reduction of approximately 2.0-2.5% from baseline of 9%, potentially achieving HbA1c <7% 3
• Dapagliflozin will contribute an additional 0.5-0.7% HbA1c reduction through its glucose-lowering effect (if eGFR ≥45 mL/min/1.73 m²) 7, 5
• Metformin provides foundational glucose control of approximately 1.0-1.5% HbA1c reduction 1

Weight Loss

• Tirzepatide provides substantial weight loss of 5-10 kg or more, with greater weight loss at higher doses 3
• Dapagliflozin contributes an additional 2-3 kg weight loss 7, 5
• This combination addresses the patient's obesity directly, unlike the previous regimen with glimepiride which causes weight gain 5

Cardiovascular and Renal Protection

• Both tirzepatide and dapagliflozin provide cardiovascular mortality reduction and heart failure hospitalization reduction through complementary mechanisms 1, 2
• Dapagliflozin slows chronic kidney disease progression and reduces risk of kidney failure by 44% 2

---

Common Pitfalls to Avoid

Do Not Continue Glimepiride "at Reduced Dose"

• Complete discontinuation is necessary, not dose reduction, given the potency of tirzepatide and the patient's obesity 4, 5

Do Not Delay Adding Dapagliflozin

• SGLT2 inhibitors should be added early for cardiovascular and renal protection, not reserved as "rescue therapy" 1, 2

Do Not Discontinue Dapagliflozin if eGFR Falls Below 45 mL/min/1.73 m²

• Cardiovascular and renal protective benefits persist even when glucose-lowering efficacy diminishes 2
• Continue dapagliflozin 10 mg daily as long as eGFR remains ≥25 mL/min/1.73 m² (or even if it falls below 25 during treatment) 2

Do Not Reduce Metformin Dose Unnecessarily

• Metformin can be safely continued at 2 grams daily unless eGFR falls below 45 mL/min/1.73 m² 1, 2